PXT 002331

Drug Profile

PXT 002331

Alternative Names: PXT002331

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator Domain Therapeutics
  • Developer Prexton Therapeutics
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 19 Sep 2016 Prexton Therapeutics completes a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT02639221)
  • 19 Sep 2016 Prexton Therapeutics plans a phase II trial for Parkinson's disease
  • 01 Jan 2016 Phase-I clinical trials in Parkinson's disease (In volunteers) in United Kingdom (PO) (NCT02639221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top